Shorts

Why Cancer Care Needs a "Both/And" Approach

Ego vs the Patient: The Hardest Medical Decision

Why Oncology is a "Black Box" for Most Primary Care Providers

The Silent Crisis in Rural Health Care

Can Quality Cancer Care Reach Rural America?

The Biggest Challenges Facing Rural Cancer Care

The Power of Perseverance: Finding Strength in Shared Journeys

Empowering Conversations: A Guide for Supporting New Diagnoses

The Best Advice From an Oncologist to a Patient

Unlocking New Possibilities in Bladder Cancer Treatment

Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC

Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer

A 13-Year-Old Drug’s Persisting Power in Prostate Cancer

Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence

Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment

Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK

Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer

The Challenge of Treating High-Risk nmCSPC

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer

Adverse Events to Watch for With Ribociclib

Dr Mayer Discusses PFS Data From evERA at ESMO 2025

How a New Drug is Changing Breast Cancer Treatment Forever

1 in 3 Breast Cancer Patients at High Risk

Why Understanding Tumor Biology is Key to Better Breast Cancer Care

FDA Requires 5 Years of Follow Up—Is It Too Much?

How Breast Cancer Treatment Became More Personalized & Effective

Reviewing the FDA Draft Guidance on Radiopharmaceuticals

Advantages of NK Cell Therapy

Understanding High-Risk Smoldering Multiple Myeloma

Looking Ahead From DeLLphi-303